Key Highlights
- Third-quarter net loss contracted to USD 0.18 per share, or USD 3.16 million in total, against a USD 0.28 per-share loss (USD 3.56 million) a year earlier, as research outlays fell 73% to USD 0.32 million.
- Management projects that cash of USD 11.5 million at September 30, 2026, which compares with USD 24.7 million at year-end, will fund operations only into the first quarter of 2027.
- The filing raises going-concern doubt, with an accumulated Deficit at USD 197.8 million and operating cash used over the first nine months of USD 19.1 million.
- Shipments of DARE to PLAY sildenafil cream should commence in November 2026 in 28 states, though the company anticipates little material Revenue for 2026.
Grant-Backed Research Shrinks the Quarterly Deficit
On November 16, 2026, Daré Bioscience (NASDAQ:DARE) lodged the report for the quarter ended September 30. Losses came in at USD 3,157,936 compared with USD 3,562,766 a year earlier, a reduction of 11%. Operating losses also shrank, moving to USD 3.09 million from USD 3.67 million. Revenue of USD 47,628 rose from a USD 2,262 base and came mostly from Research and Development services performed for a foundation under contract. The firm concentrates on women's health, from contraception to menopause, and pairs FDA development with a Section 503B compounding route. Overheads in the selling, general and administrative lines rose 6% to USD 2.64 million, including USD 0.2 million of deferred offering costs that were written down.
Going-Concern Doubt Sits Alongside USD 11.5 Million in Cash
Cash and cash equivalents shrank to USD 11,531,684 from USD 24,711,356 on December 31, 2025, while Working Capital stood near USD 3.2 million. Deferred grant money of USD 11.2 million, mostly linked to DARE-LARC1, Ovaprene Phase 3 and DARE-HPV work, is recorded as a liability. Leadership says current cash meets operating needs, including the DARE to PLAY rollout, until the first quarter of 2027. Accumulated losses total USD 197.8 million, and the firm cautions that equity, Debt or grant capital raised later could dilute existing holders. The share count reached 19,669,083 by November 13, 2026, and the nine-month loss amounted to USD 9.1 million, equal to USD 0.59 per share.
Ovaprene Study and DARE to PLAY Set the Next Tests
The pivotal Phase 3 Ovaprene trial, run by Daré Bioscience (NASDAQ:DARE), tests a hormone-free monthly contraceptive ring and is still recruiting. An independent safety panel examined 399 participants and 1,789 menstrual cycles. In August 2026 the FDA accepted a protocol amendment, while warning that the adjusted study may fall short of producing evidence strong enough for approval. Discussions with the regulator will continue. Commercially, DARE to PLAY dispensing should begin in November 2026. Separately, the consumer probiotic Flora Sync LF5 hit the market in June 2026, and a grant instalment worth USD 0.9 million came in on November 13, 2026. Main risks involve dilution, contention over trial design and sluggish early sales.
Where Things Stand
Management's own calculations say no: the cash runs only through the first quarter of 2027. Daré Bioscience (NASDAQ:DARE) reports cash of USD 11.5 million, set against a quarterly loss of USD 3.2 million, yet cash burn over nine months reached USD 19.1 million and the going-concern caution points to new funding in 2027. Grant receipts of USD 11.2 million and smaller research costs helped narrow the loss. Watch for the DARE to PLAY dispensing start, FDA talks on the Ovaprene design and any financing announcement.






Please wait processing your request...